A Phase I/II Clinical Study Evaluating Safety, Tolerability, and Efficacy of IAP0971 in Advanced Tumors
Latest Information Update: 21 Jan 2025
At a glance
- Drugs IAP 0971 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors SUNHO (China) BioPharmaceutical
Most Recent Events
- 15 Jan 2025 Status changed from not yet recruiting to recruiting.
- 04 Sep 2024 New trial record